Literature DB >> 34406793

When Less Is More: Reevaluating the Role of Intensive Chemotherapy for Older Adults With Acute Myeloid Leukemia in the Modern Era.

Nicholas J Short1, Hagop Kantarjian1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34406793      PMCID： PMC8478366          DOI： 10.1200/JCO.21.00960

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  29 in total

1.  Survival for older patients with acute myeloid leukemia: a population-based study.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Authors:  Hagop Kantarjian; Susan O'brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

4.  Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.

Authors:  Pankit Vachhani; Raed Al Yacoub; Austin Miller; Fan Zhang; Tara L Cronin; Evelena P Ontiveros; James E Thompson; Elizabeth A Griffiths; Eunice S Wang
Journal:  Leuk Res       Date:  2018-10-25       Impact factor: 3.156

5.  Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.

Authors:  A H Goldstone; A K Burnett; K Wheatley; A G Smith; R M Hutchinson; R E Clark
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

6.  Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.

Authors:  Amer M Zeidan; Nikolai A Podoltsev; Xiaoyi Wang; Chi Zhang; Jan Philipp Bewersdorf; Rory M Shallis; Scott F Huntington; Natalia Neparidze; Smith Giri; Steven D Gore; Amy J Davidoff; Xiaomei Ma; Rong Wang
Journal:  Blood Adv       Date:  2020-04-28

7.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

Review 8.  Acute myeloid leukaemia.

Authors:  Nicholas J Short; Michael E Rytting; Jorge E Cortes
Journal:  Lancet       Date:  2018-08-02       Impact factor: 79.321

9.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

10.  Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.

Authors:  Pierre-Yves Dumas; Sarah Bertoli; Emilie Bérard; Clémence Médiavilla; Edwige Yon; Suzanne Tavitian; Thibaut Leguay; Françoise Huguet; Edouard Forcade; Noël Milpied; Audrey Sarry; Mathieu Sauvezie; Pierre Bories; Arnaud Pigneux; Christian Récher
Journal:  Oncotarget       Date:  2017-03-07
View more
  3 in total

Review 1.  Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells.

Authors:  Jialan Niu; Danyue Peng; Lingbo Liu
Journal:  Front Oncol       Date:  2022-07-05       Impact factor: 5.738

2.  Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.

Authors:  Nicholas J Short; Sangeetha Venugopal; Wei Qiao; Tapan M Kadia; Farhad Ravandi; Walid Macaron; Courtney D Dinardo; Naval Daver; Marina Konopleva; Gautam Borthakur; Elizabeth J Shpall; Uday Popat; Richard E Champlin; Rohtesh Mehta; Gheath Al-Atrash; Betul Oran; Elias Jabbour; Guillermo Garcia-Manero; Ghayas C Issa; Guillermo Montalban-Bravo; Musa Yilmaz; Abhishek Maiti; Hagop Kantarjian
Journal:  J Hematol Oncol       Date:  2022-01-29       Impact factor: 17.388

3.  Is allogeneic transplantation the preferred therapy for older patients with acute myeloid leukemia?

Authors:  Arnold Ganser
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.